Search

Becton Dickinson and Co

Slēgts

SektorsVeselības aprūpe

156.15 1.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

156.08

Max

156.7

Galvenie mērījumi

By Trading Economics

Ienākumi

-692M

-310M

Pārdošana

-538M

4.7B

P/E

Sektora vidējais

27.635

62.58

EPS

2.9

Dividenžu ienesīgums

2.64

Peļņas marža

-6.576

Darbinieki

60,000

EBITDA

-499M

709M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+14% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.64%

2.19%

Nākamie ieņēmumi

2026. g. 6. aug.

Nākamais dividenžu datums

2026. g. 29. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

945M

43B

Iepriekšējā atvēršanas cena

154.2

Iepriekšējā slēgšanas cena

156.15

Ziņu noskaņojums

By Acuity

50%

50%

152 / 340 Rangs Healthcare

Becton Dickinson and Co Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. jūl. 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

2026. g. 23. jūl. 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

2026. g. 21. jūl. 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

2026. g. 20. jūl. 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Salīdzinājums

Cenas izmaiņa

Becton Dickinson and Co Prognoze

Cenas mērķis

By TipRanks

14% augšup

Prognoze 12 mēnešiem

Vidējais 178.25 USD  14%

Augstākais 204 USD

Zemākais 161 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Becton Dickinson and Co — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

4

Pirkt

4

Turēt

0

Pārdot

Noskaņojums

By Acuity

152 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat